HOXA9 and lung carcinoma: This is in range with findings by Wrangle et al. [25], who reported meth-HOXA9 with a sensitivity of 97% in lung cancer data from the Cancer Genome Atlas, and 90% and 73%, respectively, in independent cohorts from the United States and Japan.